Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of November 2009. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a new issue of securities and an application for quotation.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes.
- Ordinary Shares Issued: 750,000 new ordinary shares issued at $Nil consideration.
- Options Issued: 13,500,000 new unlisted options issued at $Nil consideration.
- Total Quoted Securities: 233,800,871 Ordinary Shares (PBT) as of the filing date.
- Dividend Policy: Unchanged for the increased capital.
Material Changes and New Issue Details
The primary material change is the issuance of securities pursuant to resolutions passed at the 2009 Annual General Meeting (AGM). The securities were entered into uncertificated holdings on November 27, 2009.
| Security Class | Quantity Issued | Exercise Price | Expiry Date | Purpose |
|---|---|---|---|---|
| Unlisted Options (Class A) | 10,000,000 | AUD $0.30 | 11 Sep 2013 | Resolution 2 of 2009 AGM |
| Ordinary Shares | 750,000 | N/A | N/A | Resolution 3 of 2009 AGM |
| Unlisted Options (Class C) | 3,500,000 | AUD $0.30 | 23 Sep 2012 | Resolution 4 of 2009 AGM |
All new securities rank equally with existing quoted securities upon exercise (for options) or allotment (for shares).
Outlook, Risks, and Management Commentary
The filing contains no management commentary, financial guidance, or specific risk factors beyond standard regulatory warranties. The company warrants that the issue complies with the law, is not for an illegal purpose, and that no person has a right to return the securities under the Corporations Act at the time of quotation.
Investor Verification Checklist
- Verify the impact of the 13,500,000 new options and 750,000 shares on existing shareholder dilution.
- Confirm the specific terms of the 2009 AGM resolutions (Resolutions 2, 3, and 4) referenced as the basis for the issue.
- Review the total outstanding option pool, which includes multiple classes with varying expiry dates and exercise prices (e.g., some expiring as early as November 2009).
- Note that the issue price was $Nil, indicating these were likely issued as part of an employee incentive plan or similar non-cash consideration arrangement.